{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:12Z","timestamp":1707524352668},"reference-count":4,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,12]]},"DOI":"10.7759\/cureus.17902","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T12:14:55Z","timestamp":1631448895000},"source":"Crossref","is-referenced-by-count":0,"title":["Adenomyosis or Not: The Ambiguity of Diagnostic Results and Clinician Incertitude"],"prefix":"10.7759","author":[{"given":"Fatimah","family":"Rajabally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Alkhaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassenjee","family":"Joomye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17242.1","article-title":"Recent advances in understanding and managing adenomyosis","volume":"8","author":"Vannuccini S","year":"2019","unstructured":"Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019, 8:F1000 Faculty Rev-283. 10.12688\/f1000research.17242.1","journal-title":"F1000Res"},{"key":"ref2","article-title":"Adenomyosis: Disease, uterine aging process leading to symptoms, or both?","volume":"12","author":"Protopapas A","year":"2020","unstructured":"Protopapas A, Grimbizis G, Athanasiou S, Loutradis D. Adenomyosis: Disease, uterine aging process leading to symptoms, or both?. Facts Views Vis Obgyn. 2020, 12:91-104.","journal-title":"Facts Views Vis Obgyn"},{"key":"ref3","unstructured":"HE4 Biomarker Test Is Approved for Use in Risk of Ovarian Malignancy Algorithm (ROMA). (2011). Accessed. 1 August 2021: https:\/\/www.cancernetwork.com\/view\/he4-biomarker-test-approved-use-risk-ovarian-malignancy-algorithm-roma."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/uog.14806","article-title":"Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group","volume":"46","author":"Van den Bosch T","year":"2015","unstructured":"Van den Bosch T, Dueholm M, Leone FP, et al.. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015, 46:284-98. 10.1002\/uog.14806","journal-title":"Ultrasound Obstet Gynecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68614-adenomyosis-or-not-the-ambiguity-of-diagnostic-results-and-clinician-incertitude","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:00Z","timestamp":1707507240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68614-adenomyosis-or-not-the-ambiguity-of-diagnostic-results-and-clinician-incertitude"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":4,"URL":"https:\/\/doi.org\/10.7759\/cureus.17902","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,12]]}}}